Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report released on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Trading Up 31.6 %

JAGX opened at $0.12 on Friday. Jaguar Health has a 1 year low of $0.05 and a 1 year high of $1.22. The stock has a 50-day moving average price of $0.08 and a 200-day moving average price of $0.18. The company has a quick ratio of 1.34, a current ratio of 2.00 and a debt-to-equity ratio of 6.33.

Institutional Trading of Jaguar Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new position in Jaguar Health in the 1st quarter worth approximately $1,079,000. Virtu Financial LLC lifted its stake in Jaguar Health by 76.1% in the 1st quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 99,073 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Jaguar Health by 152.3% during the 2nd quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 141,796 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Jaguar Health by 141.7% in the third quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock worth $50,000 after buying an additional 112,770 shares in the last quarter. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.